Kyverna Therapeutics Inc — Quarterly Balance Sheet (NASDAQ:KYTX)

Financials

Total revenue ————— — Gross profit ————— — Operating expenses 38.77 M41.04 M47.41 M44.41 M38.73 M 171.59 M Selling/general/admin expenses 9.58 M7.56 M9.97 M8.59 M8.27 M 34.4 M Research & development 29.19 M33.48 M37.43 M35.82 M30.46 M 137.19 M Operating income -38.77 M-41.04 M-47.41 M-44.41 M-38.73 M -171.59 M Non-Operating Income, Total 4.28 M3.55 M2.77 M2.33 M1.94 M 10.59 M Interest expense, net of interest capitalized 32 K27 K25 K14 K7 000 73 K Non-Operating Income, excl. Interest Expenses 4.29 M3.52 M2.77 M2.29 M1.88 M 10.47 M Unusual income/expense -45 K4 000-27 K22 K54 K 53 K Pretax income 43.02 M44.57 M50.16 M46.73 M40.66 M 182.11 M Equity in earnings ————— — Taxes ————— — Non-controlling/minority interest ————— — After tax other income/expense ————— — Net income before discontinued operations -34.49 M-37.49 M-44.63 M-42.08 M-36.79 M -160.99 M Discontinued operations ————— — Net income -34.49 M-37.49 M-44.63 M-42.08 M-36.79 M -160.99 M Dilution adjustment ————— — Preferred dividends ————— — Diluted net income available to common stockholders 34.49 M37.49 M44.63 M42.08 M36.79 M 160.99 M Basic earnings per share (Basic EPS) -0.66-0.74-1.03-0.98-0.85 -3.6 Diluted earnings per share (Diluted EPS) -0.66-0.74-1.03-0.98-0.85 -3.6 Average basic shares outstanding 36.7 M38.33 M43.22 M43.22 M43.28 M 168.05 M Diluted shares outstanding 36.7 M38.33 M43.22 M43.22 M43.28 M 168.05 M EBITDA ————— — EBIT ————— — Cost of revenue ————— — Other cost of goods sold ————— — Depreciation & amortization (cash flow) 558 K563 K501 K515 K415 K 1.99 M